The relationship between peroxisome proliferator-activated receptor-γ and renin: A human genetics study

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages

  Underwood, Patricia C ^a,b   Sun, Bei ^a   Williams, Jonathan S ^a   Pojoga, Luminita H ^a   Chamarthi, Bindu ^a   Lasky Su, Jessica ^a   Raby, Benjamin A ^a   Hopkins, Paul N ^c   Jeunemaitre, Xavier ^d   Brown, Nancy J ^e   Adler, Gail K ^a   Williams, Gordon H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON COLLEGE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RENIN;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN GENETICS; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM RESTRICTION; BLOOD; EDEMA; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MEDICAL GENETICS; METABOLISM; MIDDLE AGED; SKIN DISEASE;

ADULT; AFRICAN AMERICANS; ALLELES; EDEMA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, MEDICAL; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RENIN; SKIN DISEASES;

EID: 77956582828     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0270     Document Type: Article

References (19)

1. Krauss G 2003 Biochemistry of signal transduction and regulation. 3rd ed. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co.; 541
2. Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S 2003 The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation. J Clin Endocrinol Metab 88:2412-2421
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
4. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association 2003 Thiazolidinedione use, fluid retention, and congestive heart failure. A Consensus Statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948
5. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD 2005 Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866
6. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA 2004 Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308:426-433
7. Todorov VT, Desch M, Schmitt-Nilson N, Todorova A, Kurtz A 2007 Peroxisome proliferator-activated receptor-γ is involved in the control of renin gene expression. Hypertension 50:939-944
8. Hansen L, Ekstrøm CT, Tabanera Y Palacios R, Anant M, Wassermann K, Reinhardt RR 2006 The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 91:3446-3450
9. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M 2004 Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 89:1140-1145
10. Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA, Williams GH 2007 Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 49:461-466
11. Raji A, Williams GH, Jeunemaitre X, Hopkins PN, Hunt SC, Hollenberg NK, Seely EW 2001 Insulin resistance in hypertensives: effect of salt sensitivity, renin status and sodium intake. J Hypertens 19:99-105
12. Chamarthi B, Kolatkar NS, Hunt SC, Williams JS, Seely EW, Brown NJ, Murphey LJ, Jeunemaitre X, Williams GH 2007 Urinary free cortisol: an intermediate phenotype and a potential genetic marker for a salt-resistant subset of essential hypertension. J Clin Endocrinol Metab 92:1340-1346
13. Barrett JC, Fry B, Maller J, Daly MJ 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
14. International HAPMAP Consortium 2003 The International HAPMAP Project. Nature 426:789-796.
15. Fisher RA 1948 Questions and answers #14. The American Statistician 2:30
16. Seely EW, Moore TJ, Rogacz S, Gordon MS, Gleason RE, Hollenberg NK, Williams GH 1989 Angiotensin-mediated renin suppression is altered in non-modulating hypertension. Hypertension 13:31-37
17. Williams GH 1982 The renin-angiotensin system and hypertension. Clin Exp Pharmacol Physiol Suppl 7:31-40
18. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, Brosius 3rd FC, Gonzalez FJ, Vinson C, Pierre MA, Milstone DS, Mortensen RM 2007 Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethality. J Clin Invest 117:812-822
19. Hollenberg NK 1984 The renin-angiotensin system and sodium homeostasis. J Cardiovasc Pharmacol 6(Suppl 1):S176-S183